Prostate cancer markers: An update (Review) (original) (raw)

Profile image of Sunjit ParmarSunjit Parmar

2016, Biomedical Reports

visibility

description

6 pages

link

1 file

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact

Prostate Cancer, Version 2.2014

Mack Roach

Journal of the National Comprehensive Cancer Network, 2014

View PDFchevron_right

Molecular pathology of prostate cancer

Angelo Marzo

Journal of Clinical Pathology, 2005

View PDFchevron_right

Focus on prostate cancer

Angelo Marzo

Cancer Cell, 2002

View PDFchevron_right

Molecular alterations associated with prostate cancer

adalberto sanchez gomez

Central European Journal of Urology, 2018

View PDFchevron_right

Update on Screening in Prostate Cancer Based on Recent Clinical Trials

Vincenzo Gentile

Reviews on Recent Clinical Trials, 2011

View PDFchevron_right

Prostate cancer; the interface between pathology and basic scientific research

Andrew Stubbs

Seminars in Cancer Biology, 1997

View PDFchevron_right

Wagging the long tail of drivers of prostate cancer

Jeffrey Townsend

PLOS Genetics, 2019

View PDFchevron_right

Screening for Prostate Cancer: Opportunities and Challenges

Javier Hernandez

Surgical Oncology Clinics of North America, 2005

View PDFchevron_right

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

Scott Lucia

The New England Journal of Medicine, 2004

View PDFchevron_right

Prostate Cancer Risk with Positive Family History, Normal Prostate Examination Findings, and PSA Less Than 4.0 ng/mL

Javier Hernandez

Urology, 2007

View PDFchevron_right

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

1664: Pathological Assessment of High Grade Tumors in the Prostate Cancer Prevention Trial (PCPT)

Scott Lucia

The Journal of Urology, 2005

View PDFchevron_right

Epidemiologic determinants of clinically relevant prostate cancer

Thomas Wheeler

International Journal of Cancer, 2000

View PDFchevron_right

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

Bernard Candas

Urology, 1996

View PDFchevron_right

The Performance of Prostate Specific Antigen for Predicting Prostate Cancer is Maintained After a Prior Negative Prostate Biopsy

Scott Lucia

Journal of Urology, 2008

View PDFchevron_right

Tumor markers: From laboratory to clinical utility

Fred C. G. J. Sweep

Molecular & Cellular Proteomics, 2003

View PDFchevron_right

Study of serum prostate specific antigen levels in patients with prostate lesions

DrashtI Shukla

International Journal of Clinical and Diagnostic Pathology, 2021

View PDFchevron_right

Molecular genetics of prostate cancer

adnan albadran

Annals of Medicine, 2001

View PDFchevron_right

Development and external validation of a novel risk score to identify insignificant prostate cancer

Ashwin Narasimha Sridhar

Journal of Clinical Oncology, 2017

View PDFchevron_right

An Analysis of Patients with Clinically Localized High-Risk Prostate Carcinoma

Mack Roach

The Prostate Journal, 2000

View PDFchevron_right

Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

Scott Lucia

JNCI: Journal of the National Cancer Institute, 2006

View PDFchevron_right

Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention

Javier Hernandez

European Urology, 2007

View PDFchevron_right

Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

Scott Lucia

Cancer Prevention Research, 2008

View PDFchevron_right

Markers of the Basal Cell Layer of Prostate Are Effective Indicators of Its Malignant Transformation

Boris V Popov

View PDFchevron_right

Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management

Lukman Hakim

Cancer, 1994

View PDFchevron_right

Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening

Bruce Malkowicz

Archives of Internal Medicine, 2004

View PDFchevron_right

A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies

Gommert Van Koeveringe

International Urology and Nephrology, 2009

View PDFchevron_right

An Overview on Prostate Pathophysiology: New Insights into Prostate Cancer Clinical Diagnosis

Taize Augusto

Pathophysiology - Altered Physiological States, 2018

View PDFchevron_right

Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis

Helen Crowe

Pathology, 2012

View PDFchevron_right

Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer

Enrique Trilla

The International Journal of Biological Markers, 2002

View PDFchevron_right

ESUR prostate MR guidelines 2012

Jelle Barentsz

European Radiology, 2012

View PDFchevron_right

Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumors

Paul Russo

Urology, 1998

View PDFchevron_right

Heterogeneity of prostate cancer inradical prostatectomy specimens

Thomas Wheeler

Urology, 1994

View PDFchevron_right

Breast and prostate cancer: more similar than different

Stephen Birrell

Nature Reviews Cancer, 2010

View PDFchevron_right

Increased Cumulative Incidence of Prostate Malignancies in Colorectal Cancer Patients

Nuri Ozden

International Journal of Gastrointestinal Cancer, 2004

View PDFchevron_right

Editorial: Challenges in the prevention of prostate cancer

Andrea Venerando

Frontiers in Oncology, 2023

View PDFchevron_right

Medicine